Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy joining 3 (IGHJ3) is one of several *joining* (J) gene segments located in the immunoglobulin heavy-chain locus (IGH) on human chromosome 14q32.2. During B-cell development, IGHJ3 undergoes site-specific DNA recombination as part of V(D)J rearrangement, where one V (variable), one D (diversity), and one J (joining) segment are joined to create the variable region of the immunoglobulin (antibody) heavy chain. This process generates antibody diversity crucial for adaptive immunity. While IGHJ3 itself does not function as a protein, its DNA sequence is incorporated into the B-cell receptor or antibody molecule, contributing to antigen recognition and immune response. Rearranged IGH clonotypes, including those involving IGHJ3, are valuable biomarkers for identifying and tracking B-cell malignancies and responses to therapy. IGHJ3 is a germline gene segment, not a functional protein or receptor. Its primary role is in antibody gene recombination and it is utilized in diagnostic and research contexts, rather than as a direct drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy joining 3 (IGHJ3).